InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,751.07
(
0.90%
)
US TECH 100
19,476.00
(
1.10%
)
Dow Jones
42,352.75
(
0.81%
)
Brent Oil
77.97
(
0.00%
)
Bitcoin
62,207.76
(
0.21%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120534
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jessellivermore post# 3221

Saturday, 09/01/2007 5:20:58 PM

Saturday, September 01, 2007 5:20:58 PM

Post# of 19309
GTC’s Relationship With PharmAthene

[Updated and reorganized; fixed bad hyperlinks.]


#msg-4107224 Original IP license for Protexia (2004)
#msg-22544066 Protexia process and purification agreement
#msg-17826727 IP license expanded to all uses of Protexia
#msg-18433447 Protexia program in Alzheimer’s disease

#msg-13565694 Protexia grant from USDoD
#msg-14110344 Protexia grant from NIH
#msg-17587523 Biodefense drug-development timeline

#msg-22543627 PharmAthene now trades on the Amex

--
What are the economics of the relationship for GTC?

GTC has not disclosed the economic terms of the PharmAthene relationship; however, Dr. Cox did provide some color in reply to a question on GTC’s 4Q06 CC (#msg-17607391). Based on that, I think it’s conservative to assume that GTC stands to earn a mid-single-digit royalty on the sales of Protexia. The PharmAthene relationship could thus generate a non-trivial income stream for GTC, especially if the Protexia program in Alzheimer’s disease were to pan out.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up